Congress Asset Management Co. Sells 34,119 Shares of Boston Scientific Corporation $BSX

Congress Asset Management Co. decreased its position in Boston Scientific Corporation (NYSE:BSX) by 2.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,649,958 shares of the medical equipment provider’s stock after selling 34,119 shares during the quarter. Boston Scientific accounts for approximately 1.1% of Congress Asset Management Co.’s holdings, making the stock its 17th largest holding. Congress Asset Management Co.’s holdings in Boston Scientific were worth $157,323,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of BSX. Gerber Kawasaki Wealth & Investment Management grew its holdings in shares of Boston Scientific by 3.8% during the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after buying an additional 99 shares in the last quarter. Crown Wealth Group LLC boosted its position in Boston Scientific by 4.7% during the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after acquiring an additional 100 shares during the last quarter. Claret Asset Management Corp boosted its position in Boston Scientific by 4.4% during the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after acquiring an additional 102 shares during the last quarter. Cary Street Partners Investment Advisory LLC grew its stake in shares of Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after acquiring an additional 103 shares in the last quarter. Finally, Scotia Capital Inc. grew its stake in shares of Boston Scientific by 0.7% during the 2nd quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock worth $1,621,000 after acquiring an additional 104 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Needham & Company reiterated a “Buy” rating on BSX, reinforcing institutional support for the shares amid the post-earnings pullback; this helps underpin demand from investors looking for growth exposure in medical devices. Boston Scientific’s (BSX) “Buy” Rating Reiterated at Needham & Company LLC
• Neutral Sentiment: Several market write-ups argue the pullback could be a buying opportunity given solid recent fundamentals (beat on adjusted EPS, strong free cash flow, growth in EP and Watchman) and potential catalysts such as Champion-AF trial results and the planned Penumbra acquisition — but these are contingent on upcoming clinical and integration outcomes. Is Boston Scientific (BSX) Still Attractive After Its Recent Share Price Pullback?
• Negative Sentiment: Multiple law firms have filed or are soliciting clients for a securities class action covering purchases between July 23, 2025 and Feb 3, 2026; they remind investors of a May 4, 2026 lead-plaintiff deadline — this increases legal overhang and potential litigation costs/settlement risk. ROSEN – Class Action Notice Robbins LLP – Class Action Alert Faruqi & Faruqi – Class Action Notice
• Negative Sentiment: MassDevice reports alleged long-running pacemaker battery problems — product reliability and potential recalls or regulatory scrutiny could materially affect device sales and margins if issues are confirmed and widespread. Boston Scientific has reportedly had pacemaker battery problems for years
• Negative Sentiment: Stifel cut its price target on BSX to $90, signaling some analyst caution and reduced near-term upside expectations even where ratings remain constructive — this can weigh on sentiment and caps potential rebound momentum. Stifel Nicolaus Cuts Boston Scientific Price Target to $90

Boston Scientific Price Performance

Shares of NYSE BSX opened at $69.54 on Tuesday. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The business’s 50 day moving average price is $79.22 and its two-hundred day moving average price is $91.68. The company has a market cap of $103.34 billion, a PE ratio of 35.84, a price-to-earnings-growth ratio of 0.97 and a beta of 0.69. Boston Scientific Corporation has a twelve month low of $67.56 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s revenue was up 15.9% on a year-over-year basis. During the same period last year, the firm posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on BSX. Citigroup cut their price objective on shares of Boston Scientific from $102.00 to $94.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Canaccord Genuity Group decreased their target price on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. TD Cowen lowered their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Sanford C. Bernstein reissued an “outperform” rating and set a $112.00 price target on shares of Boston Scientific in a research report on Friday, February 6th. Finally, Robert W. Baird reduced their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $106.27.

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.